# Flowchart for the use of Ocular Lubricants in Dry Eye Disease Assess severity of dry eyes

Ocular discomfort: MILD

Frequency of discomfort: episodic Visual symptoms: None/episodic

mild fatique

Conjunctival staining: None to

mild

Corneal staining: None to mild Tear break-up time: variable Schirmer score (mm/5 minutes): variable

Ocular discomfort: **MODERATE** 

Frequency of discomfort: episodic

or chronic

Visual symptoms: episodic,

activity limiting

Conjunctival staining: variable Corneal staining: variable

Tear break-up time: ≤ 10 seconds Schirmer score: ≤ 10 mm at 5

minutes

Ocular discomfort: **SEVERE** 

Frequency of discomfort: constant

and disabling

Visual symptoms: constant limiting

activity, disabling

Conjunctival staining: moderate to

marked

Corneal staining: marked, severe

punctate erosions

Corneal signs: Filamentary keratitis, mucus clumping, increased tear debris, corneal ulceration

Tear break-up time: ≤ 5 seconds Schirmer score: ≤ 5 mm at 5 minutes

#### Mild dry eyes (Grade 1)\*

#### Moderate dry eyes (Grade 2)\*

### Severe dry eyes (Grades 3 or 4)\*



Consider one of the following 4 times a day+/- ointment (e.g. Lacri-Lube®) at night:

Preserved (supplied in a bottle/tubes)

Hypromellose 0.5% Carbomers



Consider a preservative free preparation (6 or more times a day) and ointment (e.g. Lacri-Lube®) at night:

Multidose bottle - preservative free

Sodium hyaluronate (e.g. Hyabak® 0.15%; Hylo-Forte® 0.2%)



- 1. Refer to Cornea and External Eye Disease Clinic
- 2. Patients may need the following in addition to / instead of any of the above-mentioned lubricants:
  - Sodium hyaluronate (e.g. Vismed® 0.18%, Clinitas® 0.4%)
  - Acetylcysteine
  - Anti-inflammatory agents

Preservative free (if patient intolerant to preservatives / unsuitable for preservatives e.g. already on frequent preserved eye drops for co-existing ocular conditions)

Polyvinyl alcohol e.g. Refresh Ophthalmic®

Single dose units – preservative free

Polyvinyl alcohol e.g. Refresh **Ophthalmic®** 

Hydroxypropyl-guar (e.g. Systane®)

Carmellose (e.g. Celluvisc® 1% or if not tolerated 0.5%)

# References:

- Behrens A, Doyle J J, Stern L, et al. Dysfunctional tear syndrome. A Delphi approach to treatment 1. recommendations. Cornea 2006; 25:900-7
- 2. Management and therapy of dry eye disease: report of the Management and Therapy Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf 2007; 5(2):163-178.

Authors: Mr Anil Aralikatti, Consultant; Lucy Titcomb, Lead Ophthalmic Pharmacist Approved by: Drugs and Therapeutic Committee Divisional Governance Group - Surgery B Reviewed: December 2013